相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1
Hongzhong Li et al.
CANCER CELL (2022)
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
A. Filippone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Joseph J. Zhao et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
David M. O'Malley et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
Caicun Zhou et al.
LANCET ONCOLOGY (2022)
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial (vol 27, pg 1536, 2021)
Hai-Qiang Mai et al.
NATURE MEDICINE (2022)
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Y. Doki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
Zhi Qi et al.
NATURE COMMUNICATIONS (2022)
Probiotics in microbiome ecological balance providing a therapeutic window against cancer
Nirmala Sehrawat et al.
SEMINARS IN CANCER BIOLOGY (2021)
Reinvigorating exhausted CD8+cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
Md Amir Hossain et al.
MEDICINAL RESEARCH REVIEWS (2021)
Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma
Changrong Wang et al.
BIOMATERIALS (2021)
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
Yuanyuan Zhang et al.
CANCER CELL (2021)
Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids
Vivien Koh et al.
CANCER LETTERS (2021)
Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
Khiem C. Lam et al.
CELL (2021)
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Makoto Nishio et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer
Antonio Passaro et al.
LANCET ONCOLOGY (2021)
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
Sadna Budhu et al.
CELL REPORTS (2021)
The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1
Hui Li et al.
ADVANCED SCIENCE (2021)
Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling
Christophe Glorieux et al.
REDOX BIOLOGY (2021)
PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B
Shangyun Lu et al.
CANCER SCIENCE (2021)
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2021)
Mutant clones in normal epithelium outcompete and eliminate emerging tumours
B. Colom et al.
NATURE (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen et al.
NATURE MEDICINE (2021)
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Tina Cascone et al.
NATURE MEDICINE (2021)
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
Clemens Hinterleitner et al.
NATURE COMMUNICATIONS (2021)
An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
Shuguang Zuo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
Qingda Meng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids
Jayati Chakrabarti et al.
CANCERS (2021)
Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy
Kewen Lei et al.
NATURE BIOMEDICAL ENGINEERING (2021)
Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma
Lei Guo et al.
LIFE SCIENCES (2021)
Energy status dictates PD-L1 protein abundance and anti-tumor to enable blockade
Xiaoming Dai et al.
MOLECULAR CELL (2021)
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Zowi R. Huinen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Evan W. Weber et al.
SCIENCE (2021)
Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression
Hong Zhang et al.
ADVANCED SCIENCE (2021)
Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+T cells in deficient mismatch repair colorectal cancer
Qiaoqi Sui et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
Lu Cao et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
Shangqin Sun et al.
CANCERS (2021)
The Yin and Yang of Discoidin Domain Receptors (DDRs): Implications in Tumor Growth and Metastasis Development
Sandra Majo et al.
CANCERS (2021)
Patient-Derived Cancer Organoids as Predictors of Treatment Response
Maikel Verduin et al.
FRONTIERS IN ONCOLOGY (2021)
Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy
Yupeng Wang et al.
ADVANCED MATERIALS (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
Yujue Wang et al.
CANCER CELL (2021)
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
Yan Lan et al.
CANCER CELL (2021)
M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Xinyao Qiu et al.
CANCER RESEARCH (2021)
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Kazuhiro Koikawa et al.
CELL (2021)
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Corey C. Foster et al.
CLINICAL CANCER RESEARCH (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
Xiaoxiang Zhou et al.
LANCET ONCOLOGY (2021)
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Benjamin C. Creelan et al.
NATURE MEDICINE (2021)
Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways
Zhen Xiang et al.
ONCOGENE (2021)
Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
Janna Krueger et al.
PLOS ONE (2021)
Developmental chromatin programs determine oncogenic competence in melanoma
Arianna Baggiolini et al.
SCIENCE (2021)
Opposing roles of the immune system in tumors
Won Jin Ho et al.
SCIENCE (2021)
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
Amaia Martinez-Usatorre et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Cecile Geuijen et al.
NATURE COMMUNICATIONS (2021)
Establishment of patient-derived organotypic tumor spheroid models for tumor microenvironment modeling
Hye Kyung Hong et al.
CANCER MEDICINE (2021)
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer The Phase 2 KEYNOTE-799 Nonrandomized Trial
Salma K. Jabbour et al.
JAMA ONCOLOGY (2021)
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
Si-Yu Wu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
Yaohui Gao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial
Aparna R. Parikh et al.
NATURE CANCER (2021)
Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer
Yi Ban et al.
NATURE CANCER (2021)
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Roman M. Chabanon et al.
NATURE REVIEWS CANCER (2021)
Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
Eleni Panagioti et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
Haiping Jiang et al.
ONCOIMMUNOLOGY (2021)
A snapshot of the PD-1/PD-L1 pathway
Chinmoy Ghosh et al.
JOURNAL OF CANCER (2021)
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Changxin Wan et al.
CANCER RESEARCH (2021)
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype for updates and increased immunogenicity
Chengming Liu et al.
CANCER LETTERS (2020)
The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals
Elliot A. Philips et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells
Haifang Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
Rebecca A. Luchtel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
High-dose vitamin C enhances cancer immunotherapy
Alessandro Magri et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer
John Kwon et al.
CANCER DISCOVERY (2020)
Molecular mechanism of SHP2 activation by PD-1 stimulation
M. Marasco et al.
SCIENCE ADVANCES (2020)
Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression
Man-Chin Chen et al.
CANCERS (2020)
Acquired Resistance to Immune Checkpoint Inhibitors
Adam J. Schoenfeld et al.
CANCER CELL (2020)
Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study
Giovanni Lo Re et al.
CYTOKINE (2020)
Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
Alok Kumar et al.
ELIFE (2020)
Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases
Lin Zhang et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
The Role of PD-1 in Acute and Chronic Infection
Jil M. Jubel et al.
FRONTIERS IN IMMUNOLOGY (2020)
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Luca Mazzarella et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Characterization of human cancer xenografts in humanized mice
Jonathan Rios-Doria et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells
Rudi Mao et al.
CANCER SCIENCE (2020)
Multistage Sensitive NanoCRISPR Enable Efficient Intracellular Disruption of Immune Checkpoints for Robust Innate and Adaptive Immune Coactivation
Ning Wang et al.
ADVANCED FUNCTIONAL MATERIALS (2020)
Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1
Suxing Jin et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Adham S. Bear et al.
CANCER CELL (2020)
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
Florida Voli et al.
CANCER RESEARCH (2020)
Fasting-mimicking diet and hormone therapy induce breast cancer regression
Irene Caffa et al.
NATURE (2020)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio et al.
LANCET ONCOLOGY (2020)
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Hye-Jung Kim et al.
TRENDS IN IMMUNOLOGY (2020)
Toll-Like Receptor 9 Agonists in Cancer
Lilit Karapetyan et al.
ONCOTARGETS AND THERAPY (2020)
KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity
Xizi Jiang et al.
CELL AND BIOSCIENCE (2020)
Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma
Loryn Holokai et al.
CANCERS (2020)
Physical Plasma-Treated Skin Cancer Cells Amplify Tumor Cytotoxicity of Human Natural Killer (NK) Cells
Ramona Clemen et al.
CANCERS (2020)
Educational attainment in displaced children with cancer Comment
Carlene Wilson et al.
LANCET ONCOLOGY (2020)
Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
Takaaki Oba et al.
NATURE COMMUNICATIONS (2020)
Vitamin C: A stem cell promoter in cancer metastasis and immunotherapy
Jingwen Fu et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Immunotherapy as sensitizer for local radiotherapy
Ben G. L. Vanneste et al.
ONCOIMMUNOLOGY (2020)
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
Qibin Liao et al.
BIOMARKER RESEARCH (2020)
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab
Ramy M. Hanna et al.
SAGE OPEN MEDICAL CASE REPORTS (2020)
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy
Qianmei Yang et al.
THERANOSTICS (2020)
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Shruthy Suresh et al.
NATURE CANCER (2020)
Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export
Fang-Fang Chen et al.
ONCOIMMUNOLOGY (2020)
Serotonin and human cancer: A critical view
Denis Sarrouilhe et al.
BIOCHIMIE (2019)
Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
Xiaoqing Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC
Fabrice Barlesi et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Hyun Tae Lee et al.
MOLECULES (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection
Loryn Holokai et al.
PLOS PATHOGENS (2019)
PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
Jing Li et al.
FUTURE ONCOLOGY (2019)
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis
Andrew M. Frederickson et al.
IMMUNOTHERAPY (2019)
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
Piao Li et al.
JOURNAL OF IMMUNOLOGY (2019)
Development of the Inhibitors That Target the PD-1/PD-L1 InteractionA Brief Look at Progress on Small Molecules, Peptides and Macrocycles
Katarzyna Guzik et al.
MOLECULES (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
Alfredo Addeo et al.
FRONTIERS IN ONCOLOGY (2019)
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Davide Ciardiello et al.
CANCER TREATMENT REVIEWS (2019)
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
Carminia Maria Della Corte et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract
Kiichiro Teruya et al.
MARINE DRUGS (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Vitamin C Loaded Poly(urethane-urea)/ZnA-LDH Aligned Scaffolds Increase Proliferation of Corneal Keratocytes and Up-Regulate Vimentin Secretion
Mojgan Moghanizadeh-Ashkezari et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer
Bin Liu et al.
ACTA BIOMATERIALIA (2019)
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Jiajing Cai et al.
ONCOTARGETS AND THERAPY (2019)
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Weiting Qin et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Manni Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma
Hailong Ma et al.
BRITISH JOURNAL OF CANCER (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
The brain-immune cells axis controls tissue specific immunopathology
Maxi Heyner et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells
Wenyi Gu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2019)
Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade
Hong Jae Chon et al.
CLINICAL CANCER RESEARCH (2019)
IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1
Emma Eriksson et al.
JOURNAL OF IMMUNOLOGY (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy
Gang Shi et al.
MOLECULAR THERAPY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis
Xiaobo Li et al.
CELLS (2019)
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
Yang Zhang et al.
RESPIRATORY RESEARCH (2019)
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Li Jiang et al.
SCIENTIFIC REPORTS (2019)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2018)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
NFATc1 Promotes Antitumoral Effector Functions and Memory CD8(+) T-cell Differentiation during Non-Small Cell Lung Cancer Development
Lisanne Heim et al.
CANCER RESEARCH (2018)
EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells
Yang Wang et al.
CELL CYCLE (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
John A. Thompson
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
Lijun Xu et al.
MOLECULAR ONCOLOGY (2018)
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis et al.
NATURE MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Mirjana Efremova et al.
NATURE COMMUNICATIONS (2018)
Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors
Cancer Discovery (2018)
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes
Konrad Gabrusiewicz et al.
ONCOIMMUNOLOGY (2018)
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
Yiwen Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
Samuel F. Bakhoum et al.
CELL (2018)
Role of hypoxia-induced exosomes in tumor biology
Chuchu Shao et al.
MOLECULAR CANCER (2018)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong-Ho Cha et al.
MOLECULAR CELL (2018)
Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
Anchalee Rawangkan et al.
MOLECULES (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Organoid Modeling of the Tumor Immune Microenvironment
James T. Neal et al.
CELL (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Application of atomic force microscopy in cancer research
Xiangying Deng et al.
JOURNAL OF NANOBIOTECHNOLOGY (2018)
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
George Fromm et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Tumor immune evasion arises through loss of TNF sensitivity
Conor J. Kearney et al.
SCIENCE IMMUNOLOGY (2018)
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors
Ee Lyn Lim et al.
JCI INSIGHT (2018)
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie-Nicole Theodoraki et al.
CLINICAL CANCER RESEARCH (2018)
High Expression of lncRNA AFAP1-AS1 Promotes the Progression of Colon Cancer and Predicts Poor Prognosis
Hao Bo et al.
JOURNAL OF CANCER (2018)
BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM
Fang Wei et al.
BRITISH JOURNAL OF CANCER (2018)
Cross-talk between TNF-alpha and IFN-gamma signaling in induction of B7-H1 expression in hepatocellular carcinoma cells
Na Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Organoids: A historical perspective of thinking in three dimensions
Marina Simian et al.
JOURNAL OF CELL BIOLOGY (2017)
Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory
Alexander P. R. Bally et al.
JOURNAL OF IMMUNOLOGY (2017)
Immunotherapy of cancers comes of age
Hila Yousefi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
Xun Wang et al.
IMMUNOLOGY LETTERS (2017)
Analysis of Immune Correlates Using Anti-PD-1 Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy
S. Kim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Targeting Immune Checkpoints in Cancer Therapy
Suzanne L. Topalian
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
MicroRNA-155 induction via TNF- and IFN- suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
Daniel Yee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Bingshan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer
Xiaomei Gong et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
Tim Wartewig et al.
NATURE (2017)
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu et al.
NATURE (2017)
cGAS surveillance of micronuclei links genome instability to innate immunity
Karen J. Mackenzie et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1
Gang Chen et al.
NATURE NEUROSCIENCE (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer
J. Wang et al.
ONCOGENE (2017)
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak et al.
STRUCTURE (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway
Ming Jing Shen et al.
ONCOTARGET (2017)
The role of exosomal non-coding RNAs in cancer metastasis
Jin-Peng Wang et al.
Oncotarget (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells
Fang Zheng et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Role of tumor microenvironment in tumorigenesis
Maonan Wang et al.
JOURNAL OF CANCER (2017)
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
Howard Y. Li et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Intratumoral immunotherapy: using the tumor as the remedy
A. Marabelle et al.
ANNALS OF ONCOLOGY (2017)
Tumor-derived exosomes modulate PD-L1 expression in monocytes
Franziska Haderk et al.
SCIENCE IMMUNOLOGY (2017)
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley et al.
CLINICAL CANCER RESEARCH (2017)
Inflammatory cytokines compromise programmed cell death-1(PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1
D. Bommarito et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors
Kiyonori Tanoue et al.
CANCER RESEARCH (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy
Panpan Zhang et al.
CANCER SCIENCE (2016)
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Thomas K. Eigentler et al.
CANCER TREATMENT REVIEWS (2016)
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Weimin Wang et al.
CELL (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Andy J. Minn et al.
CELL (2016)
MYC - a thorn in the side of cancer immunity
Stefani Spranger et al.
CELL RESEARCH (2016)
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
Masaki Mandai et al.
CLINICAL CANCER RESEARCH (2016)
Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion
Bertram Bengsch et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Nan Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
Tessa Gargett et al.
MOLECULAR THERAPY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Jonathan T. Sockolosky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Dimitrios Mathios et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial
Joanna E. Long et al.
VACCINE (2016)
The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
Kankana Bardhan et al.
FRONTIERS IN IMMUNOLOGY (2016)
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
Hidetoshi Sumimoto et al.
PLOS ONE (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
Elly Marcq et al.
CANCER TREATMENT REVIEWS (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay et al.
CELL (2015)
Extracellular vesicles shuffling intercellular messages: for good or for bad
Alessandra Lo Cicero et al.
CURRENT OPINION IN CELL BIOLOGY (2015)
The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma
Natalie Spaccarelli et al.
DERMATOLOGIC CLINICS (2015)
Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Timothy J. Daskivich et al.
EUROPEAN UROLOGY (2015)
Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells
Sanja Stevanovic et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Human PD-1 binds differently to its human ligands: A comprehensive modeling study
Clement Viricel et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
Ahmad A. Tarhini et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Roy L. Maute et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Erika Vacchelli et al.
SCIENCE (2015)
New immunotherapies targeting the PD-1 pathway
Jordan M. Chinai et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Several immune escape patterns in non-Hodgkin's lymphomas
Camille Laurent et al.
ONCOIMMUNOLOGY (2015)
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?
Guido Kroemer et al.
ONCOIMMUNOLOGY (2015)
The role of serotonin and its receptors in activation of immune responses and inflammation
M. S. Shajib et al.
ACTA PHYSIOLOGICA (2015)
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
Raja Rekik et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
Shenyou Sun et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients
Andreas Pircher et al.
LUNG CANCER (2014)
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Hatem Soliman et al.
PLOS ONE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
Jennifer M. Boland et al.
CLINICAL LUNG CANCER (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
Yawei Liu et al.
JOURNAL OF NEUROSCIENCE (2013)
PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2
Nikolaos Patsoukis et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
Minmin Song et al.
PLOS ONE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Role of the PD-1 Pathway in the Immune Response
L. V. Riella et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion
Kimberly A. Hofmeyer et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
Seigo Terawaki et al.
JOURNAL OF IMMUNOLOGY (2011)
PD-L2 is expressed on activated human T cells and regulates their function
Nassima Messal et al.
MOLECULAR IMMUNOLOGY (2011)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
Elias A. Said et al.
NATURE MEDICINE (2010)
PD-1 on dendritic cells impedes innate immunity against bacterial infection
Sheng Yao et al.
BLOOD (2009)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Human Prostate-Infiltrating CD8+ T Lymphocytes are Oligoclonal and PD-I+
Karen S. Sfanos et al.
PROSTATE (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Interferon-sensitive response element (ISRE) is mainly responsible for IFN-α-induced upregulation of programmed death-1 (PD-1) in macrophages
Hae-Yun Cho et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2008)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Takeshi Azuma et al.
BLOOD (2008)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
Fumihiko Tsushima et al.
BLOOD (2007)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells
Hadi Valadi et al.
NATURE CELL BIOLOGY (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Regulation of T cell activation and tolerance by PDL2
Yongliang Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson et al.
CANCER RESEARCH (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion
PA Saunders et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism
XL Liu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy
N Selenko-Gebauer et al.
JOURNAL OF IMMUNOLOGY (2003)
The PI-3 kinase/Akt pathway and T cell activation:: pleiotropic pathways downstream of PIP3
LP Kane et al.
IMMUNOLOGICAL REVIEWS (2003)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)